MediciNova Projected to Post Earnings on Wednesday

Biopharmaceutical company MediciNova (MNOV) expected to announce quarterly results

Published on Feb. 15, 2026

Got story updates? Submit your updates here. ›

MediciNova (NASDAQ:MNOV), a biopharmaceutical company focused on developing novel small-molecule therapeutics, is expected to release its earnings results before the market opens on Wednesday, February 18. Analysts project the company will report a loss of $0.0950 per share for the quarter.

Why it matters

As a clinical-stage biopharmaceutical company, MediciNova's earnings reports provide insight into the progress and performance of its drug development pipeline, which includes treatments for neurodegenerative, inflammatory, fibrotic and oncological diseases. The company's lead asset, MN-166 (ibudilast), is an anti-inflammatory and neuroprotective agent approved in Japan.

The details

MediciNova reported a loss of $0.06 per share in the previous quarter, beating analysts' consensus estimates of a $0.08 loss. The company generated $0.12 million in revenue for the quarter. On average, analysts expect MediciNova to post $0 in earnings per share for the current fiscal year and the next fiscal year.

  • MediciNova is expected to release its earnings results before the market opens on Wednesday, February 18, 2026.

The players

MediciNova

A clinical-stage biopharmaceutical company focused on developing novel small-molecule therapeutics for neurodegenerative, inflammatory, fibrotic and oncological diseases.

Got photos? Submit your photos here. ›

The takeaway

MediciNova's upcoming earnings report will provide insight into the progress of its drug development pipeline, particularly its lead asset MN-166 (ibudilast), which is approved in Japan and being studied for various indications. Investors will be watching for updates on the company's financial performance and any developments related to its clinical programs.